Menicon Co., Ltd.

What does Menicon own?
Menicon owns a portfolio of contact lens brands and manufacturing subsidiaries. The company produces rigid gas permeable lenses under the Menicon brand, daily disposable lenses through ClearLab in Singapore, specialized rigid and soft lenses through NKL in the Netherlands, and specialized contact lenses through Menicon UK. The company also manufactures lens care solutions and is developing intraocular lenses.

Is Menicon publicly traded?
Yes, Menicon Co., Ltd. trades on the Tokyo Stock Exchange Prime Market under ticker 7780. The company is classified in the Precision Instruments industry category and has a fiscal year ending in March. Menicon was founded in February 1951 and incorporated in July 1957.

Who founded Menicon?
Menicon was founded in February 1951 by Kyoichi Tanaka, who developed Japan's first practical corneal contact lens. Tanaka was working at an optical shop when he learned about contact lenses from the wife of a US Army officer. After extensive research, he succeeded in creating a practical lens. He established the Nippon Contact Lens Research Institute in 1952 with his brother and Dr. Mizutani.

What is Menicon's main business?
Menicon manufactures and sells contact lenses and lens care products. The company is the only manufacturer in the world dedicated to all areas of contact lens-related business, including material development, lens design, manufacturing of contact lenses, and production of care solutions. Its products include rigid gas permeable lenses, daily disposables, specialty lenses, and lens care solutions.

What were Menicon's FY2026 financial results?
Menicon reported FY2026 (fiscal year ended March 2026) revenue of 125.6 billion yen, up 3.4% from FY2025. Net income was 5.92 billion yen, up 5.2% from the prior year, with a profit margin of 4.7%. Analysts forecast revenue of approximately 132.4 billion yen for FY2027, representing 3.6% growth.

What is ClearLab?
ClearLab is Menicon's Singapore-based subsidiary that manufactures daily disposable contact lenses. The facility at International Business Park opened in 2011 with an investment of $97 million and was Menicon's first production site outside Japan for daily disposables. ClearLab also houses Menicon's first R&D center in Asia outside Japan.

Where does Menicon manufacture its products?
Menicon manufactures contact lenses in Japan, Singapore, the Netherlands, the United Kingdom, and Malaysia. The Japan facilities produce RGP lenses and other products. ClearLab in Singapore produces daily disposables. NKL in the Netherlands manufactures rigid and soft made-to-order lenses. Menicon UK produces specialized lenses. The new Malaysia smart factory, launched in February 2026, produces silicone hydrogel daily disposables.

Menicon's history began in February 1951 when Kyoichi Tanaka developed Japan's first practical corneal contact lens. Tanaka was working at an optical shop when he heard about contact lenses from the wife of a US Army officer stationed in Japan. She described the concept but did not show him any actual lenses. Tanaka resolved to create his own, and after extensive study and research, he succeeded in producing a practical corneal contact lens.

In July 1952, Tanaka and his brother Toyoyasu established the Nippon Contact Lens Research Institute in cooperation with Dr. Mizutani, just before Tanaka's 21st birthday. They converted a room in their house in Kisogawa-cho, Aichi Prefecture, into a laboratory and began manufacturing and selling contact lenses on a commercial scale for the first time in Japan.

The company released its first commercial product in 1953 under the name "M.T. Contact Lens." In 1957, the business was formally incorporated as Nippon Contact Lens Co., Ltd. The company changed its name to Toyo Contact Lens Co., Ltd. in 1965 and registered the "Menicon" trademark in 1967.

Through the 1960s and 1970s, Menicon built its reputation in rigid contact lenses, developing new materials and designs that improved comfort and oxygen permeability. The company's expertise in polymer chemistry and precision manufacturing became its competitive foundation.

Menicon expanded internationally through acquisitions and subsidiary establishments. In 2006, the company acquired NKL Contactlenzen in the Netherlands, a manufacturer of rigid contact lenses based in Emmen. In 2009, Menicon acquired David Thomas Contact Lenses Ltd. in Northampton, UK, which was renamed Menicon UK. These acquisitions expanded Menicon's manufacturing footprint in Europe and added specialized lens capabilities.

In 2011, Menicon opened a new manufacturing and R&D facility in Singapore through its subsidiary ClearLab. The 6,000-square-meter facility at International Business Park represented an investment of $97 million (approximately 8 billion yen) and became Menicon's first production site outside Japan for daily disposable contact lenses. The facility also housed the company's first R&D center in Asia outside Japan.

Menicon was listed on the Tokyo Stock Exchange, where it trades on the Prime Market under ticker 7780 in the Precision Instruments category. The company has a fiscal year ending in March. As of March 2026, Menicon had capital of approximately 5.65 billion yen, 9 domestic subsidiaries, and 29 overseas subsidiaries.

In February 2026, Menicon launched its most advanced manufacturing facility globally, a smart factory in Kulim Hi-Tech Park, Malaysia. The RM1 billion investment features fully integrated automated production, logistics, warehousing, and quality control in a digitally connected ecosystem. The facility produces daily disposable silicone hydrogel contact lenses for export to markets including Japan, Germany, and the United States.

Menicon publishes sustainability information and has established environmental commitments. The company has declared its commitment to the environment through "The Menicon Declaration on the Environment" and discloses information in line with TCFD (Task Force on Climate-related Financial Disclosures) and TNFD (Task Force on Nature-related Financial Disclosures) recommendations.

The company's sustainability framework covers three areas: environment, health, and society. Menicon states that it places the highest priority on the eye health of customers and delivers safe contact lenses worldwide. The company's research and development focus on safety and innovation supports this commitment.

Menicon's new Malaysia smart factory, launched in February 2026, was designed with advanced automation and digital connectivity to enable stable, high-volume production while maintaining quality standards. The facility's export-oriented production contributes to Malaysia's position in the global ophthalmic value chain.

The company has also established initiatives for human rights as part of its sustainability framework. Menicon's global operations across over 80 countries require attention to labor standards and ethical sourcing practices in its supply chain.

As a manufacturer of medical devices, Menicon is subject to regulatory oversight in all markets where it operates. Contact lenses and lens care products are regulated as medical devices in most jurisdictions, including FDA regulations in the United States, PMDA requirements in Japan, and CE marking requirements in Europe.

Menicon has not been associated with major public controversies or regulatory enforcement actions in recent years. The company's focus on safety and its vertically integrated manufacturing process provide quality control advantages. However, as a smaller player in a market dominated by large multinational competitors, Menicon faces ongoing pressure to maintain regulatory compliance across multiple jurisdictions while operating with limited resources compared to its larger rivals.

The company's share price performance has lagged its earnings, with the stock falling approximately 17% per year over the last three years while earnings per share declined approximately 4% per year. This suggests investor concerns about the company's competitive position and growth prospects in a market dominated by larger players.